Philips signs off on CEO’s replacementImmunomedics has announced that Syncor International will distribute the radiopharmaceutical firm’s CEA-Scan colorectal cancer agent. The deal complements a distribution deal signed earlier this year
Philips signs off on CEOs replacement
Immunomedics has announced that Syncor International will distribute the radiopharmaceutical firms CEA-Scan colorectal cancer agent. The deal complements a distribution deal signed earlier this year with Bergen Brunswig (SCAN Special Report 6/98), which replaced a prior arrangement with Mallinckrodt.
Bergen Brunswig will provide nonradiolabeled CEA-Scan to Syncor, which will radiolabel the CEA-Scan with technetium at its 118 U.S. radiopharmacies, according to an Immunomedics spokesperson. Syncor, of Woodland Hills, CA, will then provide CEA-Scan to its customers in ready-to-use dosages. Syncor will also support Morris Plains, NJ-based Immunomedics with its own sales force.
What a New Meta-Analysis Reveals About PET/CT Radiotracers for csPCa
February 6th 2025The PET/CT agent 18F-PSMA-1007 offered the highest surface under the cumulative ranking curve (SUCRA) out of nine radiotracers at the patient and lesion level for detecting clinically significant prostate cancer (csPCa), according to a meta-analysis.
New CT Angiography Study Shows Impact of COVID-19 on Coronary Inflammation and Plaque
February 5th 2025Prior COVID-19 infection was associated with a 28 percent higher progression of total percent atheroma volume (PAV) annually and over a 5 percent higher incidence of high-risk plaque in patients with coronary artery lesions, according to CCTA findings from a new study.